World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
51767
World Ranking
8434
National Ranking
4360

Overview

Eric Lawitz is affiliated with The University of Texas at Austin in the United States. Their research primarily focuses on medicine, with an emphasis on hepatology, epidemiology, surgery, endocrinology, diabetes and metabolism, and oncology.

The scientist has contributed extensively to the study of liver-related diseases and conditions. Key research areas include liver disease diagnosis and treatment, liver diseases and immunity, liver disease and transplantation, hepatitis C virus research, diet, metabolism and disease, pancreatitis pathology and treatment, and gallbladder and bile duct disorders.

Eric Lawitz has published frequently in several prominent medical journals. The main publication venues include:

  • Journal of Hepatology
  • The American Journal of Gastroenterology
  • Gastroenterology
  • Hepatology
  • The Lancet Gastroenterology & Hepatology

Frequent co-authors with whom Lawitz has collaborated include:

  • Lisa D. Pedicone
  • Fabian Rodas
  • Carmen Landaverde
  • Eugenia Tsai
  • Naim Alkhouri

Notable recent papers authored or co-authored by Eric Lawitz include:

  • "Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis," 2024, New England Journal of Medicine
  • "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials," 2020, Journal of Hepatology
  • "Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial," 2023, The Lancet Gastroenterology & Hepatology
  • "Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial," 2020, Hepatology
  • "A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis," 2024, New England Journal of Medicine

Best Publications

  • Treatment of HCV Infection by Targeting MicroRNA

    Harry L A Janssen;Hendrik W Reesink;Eric J Lawitz;Stefan Zeuzem

  • Sofosbuvir for previously untreated chronic hepatitis C infection

    Eric Lawitz;Alessandra Mangia;David Wyles;Maribel Rodriguez-Torres

  • Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

    Bruce R. Bacon;Stuart C. Gordon;Eric Lawitz;Patrick Marcellin

  • Telaprevir for retreatment of HCV infection.

    Stefan Zeuzem;Pietro Andreone;Stanislas Pol;Eric Lawitz

  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

    John G. McHutchison;Eric J. Lawitz;Mitchell L. Shiffman;Andrew J. Muir

  • Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

    Nezam Afdhal;K. Rajender Reddy;David R. Nelson;Eric Lawitz

  • Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

    Mark S. Sulkowski;David F. Gardiner;Maribel Rodriguez-Torres;K. Rajender Reddy

  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

    Kris V. Kowdley;Stuart C. Gordon;K. Rajender Reddy;Lorenzo Rossaro

  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

    Ira M. Jacobson;Stuart C. Gordon;Kris V. Kowdley;Eric M. Yoshida

  • Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

    Eric Lawitz;Mark S Sulkowski;Reem Ghalib;Maribel Rodriguez-Torres

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

    Paul Y Kwo;Eric J Lawitz;Jonathan McCone;Eugene R Schiff

  • Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

    Alexander J. Thompson;Andrew J. Muir;Andrew J. Muir;Mark S. Sulkowski;Dongliang Ge

  • Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis

    M. P. Curry;J. G. O'Leary;N. Bzowej;A. J. Muir

  • All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study

    David R. Nelson;James N. Cooper;Jacob P. Lalezari;Eric Lawitz

  • Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

    Anna S. Lok;David F. Gardiner;Eric Lawitz;Claudia Martorell

  • Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

    Eric Lawitz;Fred F Poordad;Phillip S Pang;Robert H Hyland

  • Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.

    Arun Sanyal;Edgar D Charles;Brent A Neuschwander-Tetri;Rohit Loomba

  • The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

    Rohit Loomba;Eric Lawitz;Parvez S. Mantry;Saumya Jayakumar

  • Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.

    Edward Gane;Eric Lawitz;David Pugatch;Georgios Papatheodoridis

Frequent Co-Authors

Zobair M. Younossi
Zobair M. Younossi Inova Health System
Ira M. Jacobson
Ira M. Jacobson New York University
John G. McHutchison
John G. McHutchison Duke University
Mark S. Sulkowski
Mark S. Sulkowski Johns Hopkins University School of Medicine
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Andrew J. Muir
Andrew J. Muir Duke University
Kris V. Kowdley
Kris V. Kowdley Washington State University
Mitchell L. Shiffman
Mitchell L. Shiffman Bon Secours Health System
Nezam H. Afdhal
Nezam H. Afdhal Beth Israel Deaconess Medical Center
David R. Nelson
David R. Nelson University of Tennessee Health Science Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring alternative healthcare pathways beyond traditional medical school, there are several flexible online options to consider. Many aspiring healthcare professionals are looking to streamline their entry into this field, whether by bypassing certain entrance exams or advancing their credentials efficiently.

For those interested in nursing, enrolling in an lpn school without teas test can save time and reduce barriers to admission. This is an excellent choice if you want to begin your nursing career quickly.

If you aim for leadership roles, an accelerated healthcare administration degree can help fast-track your management ambitions within the healthcare industry.

Registered nurses seeking advanced practice can look into rn to fnp bridge programs that offer convenient transitions to become Family Nurse Practitioners.

For those interested in preventative medicine and wellness, earning an online degree nutrition can open doors to careers in dietetics, public health, and research.

These related online degrees offer versatile career routes in healthcare, accommodating varying interests, career stages, and educational backgrounds.

Best Scientists Citing Eric Lawitz

Trending Scientists

Recently Published Articles